Insider Selling: Arcus Biosciences (NYSE:RCUS) Insider Sells $99,587.04 in Stock

Arcus Biosciences, Inc. (NYSE:RCUS) insider Richard Markus sold 4,494 shares of Arcus Biosciences stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $22.16, for a total value of $99,587.04. Following the completion of the sale, the insider directly owned 65,647 shares of the company’s stock, valued at $1,454,737.52. This trade represents a 6.41% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Richard Markus also recently made the following trade(s):

• On Tuesday, December 16th, Richard Markus sold 5,052 shares of Arcus Biosciences stock. The shares were sold at an average price of $21.88, for a total value of $110,537.76.

Arcus Biosciences Price Performance

Arcus Biosciences stock opened at $21.99 on Friday. The business’s 50-day simple moving average is $21.10 and its 200 day simple moving average is $14.16. The company has a quick ratio of 3.65, a current ratio of 3.65 and a debt-to-equity ratio of 0.22. The stock has a market cap of $2.37 billion, a price-to-earnings ratio of -6.39 and a beta of 0.75. Arcus Biosciences, Inc. has a 12-month low of $6.50 and a 12-month high of $26.40.

Arcus Biosciences (NYSE:RCUS) last announced its quarterly earnings data on Tuesday, October 28th. The company reported ($1.27) earnings per share for the quarter, topping the consensus estimate of ($1.33) by $0.06. Arcus Biosciences had a negative return on equity of 68.17% and a negative net margin of 136.40%.The firm had revenue of $26.00 million during the quarter, compared to analysts’ expectations of $19.89 million. During the same period in the previous year, the business posted ($1.00) EPS. The company’s quarterly revenue was down 45.8% compared to the same quarter last year. As a group, research analysts anticipate that Arcus Biosciences, Inc. will post -3.15 earnings per share for the current year.

More Arcus Biosciences News

Here are the key news stories impacting Arcus Biosciences this week:

• Positive Sentiment: Arcus will present at the 44th Annual J.P. Morgan Healthcare Conference on Jan. 14, 2026 — a high?visibility forum that can accelerate investor interest, provide clinical/program updates and attract buy?side attention ahead of catalysts. Arcus to Present at JPM
• Neutral Sentiment: Recent analyst notes are mixed-to-constructive: some firms raised price targets and UBS/Bank of America reaffirmed coverage, producing a consensus “Moderate Buy” and an elevated average target — this supports upside but depends on upcoming clinical and commercial news. MarketBeat analyst summary
• Negative Sentiment: Significant, clustered insider selling occurred Dec. 16–18: CEO Terry Rosen sold large blocks (multiple filings totaling ~54k shares across two days), and other senior officers (CFO, COO, President, CAO, General Counsel and others) also sold shares — this concentrated executive selling is likely weighing on sentiment and may prompt short?term selling pressure. See CEO SEC filing for details. CEO Form 4
• Negative Sentiment: Additional insider sales (CAO Alexander Azoy, CFO Robert Goeltz II, COO Jennifer Jarrett, President Juan Jaen, General Counsel Carolyn Tang, and insider Richard Markus) were filed and aggregated to meaningful dollar amounts — investors often interpret broad leadership selling as a negative signal even when trades may be for diversification or tax reasons. InsiderTrades summary

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in RCUS. Amalgamated Bank increased its holdings in shares of Arcus Biosciences by 3.9% in the third quarter. Amalgamated Bank now owns 19,533 shares of the company’s stock worth $266,000 after acquiring an additional 736 shares in the last quarter. Creative Planning grew its position in shares of Arcus Biosciences by 2.7% in the 3rd quarter. Creative Planning now owns 29,629 shares of the company’s stock valued at $403,000 after purchasing an additional 771 shares during the period. GAMMA Investing LLC increased its stake in Arcus Biosciences by 59.1% during the 3rd quarter. GAMMA Investing LLC now owns 2,748 shares of the company’s stock worth $37,000 after purchasing an additional 1,021 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its stake in Arcus Biosciences by 8.0% during the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 17,398 shares of the company’s stock worth $142,000 after purchasing an additional 1,294 shares in the last quarter. Finally, Parallel Advisors LLC raised its holdings in Arcus Biosciences by 1.6% during the 2nd quarter. Parallel Advisors LLC now owns 88,007 shares of the company’s stock worth $716,000 after buying an additional 1,422 shares during the period. 92.89% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on RCUS shares. Citigroup reissued a “buy” rating on shares of Arcus Biosciences in a research note on Friday, December 12th. Truist Financial set a $30.00 price objective on Arcus Biosciences in a report on Friday, December 12th. Wall Street Zen upgraded Arcus Biosciences from a “sell” rating to a “hold” rating in a report on Sunday, December 14th. Weiss Ratings restated a “sell (d-)” rating on shares of Arcus Biosciences in a research report on Wednesday, October 8th. Finally, UBS Group reiterated a “buy” rating on shares of Arcus Biosciences in a research report on Monday, December 15th. Eight investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $28.89.

About Arcus Biosciences

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.